Petrelintide

Human clinical Weight Loss & Metabolism 2 sources

Petrelintide is an investigational, long-acting amylin analog being developed for chronic weight management. Research shows it promotes satiety, delays gastric emptying, and induces significant weight loss with a favorable gastrointestinal tolerability profile.

01Dosing reference

Amount

Investigational doses (e.g., 1.2 mg to 4.8 mg)

Frequency

Once weekly

Cycle

Continuous use under clinical trial protocols

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Amylin Receptor Agonism

Binds to and activates amylin and calcitonin receptors in the brain.

Satiety Induction

Promotes a feeling of fullness, suppresses glucagon secretion, and slows gastric emptying.

Weight Reduction

Leads to decreased caloric intake and clinically significant body weight reduction.

03Human evidence

Achieved up to 10.7% body weight loss at 42 weeks in adults with obesity.

Phase 2 clinical trial evaluating once-weekly petrelintide versus placebo.

Demonstrated a favorable safety profile with only a 1.5% gastrointestinal discontinuation rate.

Phase 2 trial, suggesting potentially better tolerability than current GLP-1 therapies.

04Preclinical evidence

Showed potent, balanced agonistic effects on both amylin and calcitonin receptors.

In vitro pharmacological profiling and receptor binding assays.

Demonstrated chemical stability and long-acting pharmacokinetic properties suitable for once-weekly dosing.

Preclinical pharmacokinetic models in animal studies.

05What is known vs. unknown

Reasonably established

Petrelintide is a long-acting analog of human amylin designed for once-weekly subcutaneous administration.
It induces weight loss primarily by increasing satiety and delaying gastric emptying.
Clinical trials have shown up to 10.7% weight loss over 42 weeks.
It appears to have a better gastrointestinal tolerability profile compared to some GLP-1 receptor agonists.

Unknowns & limits

Long-term cardiovascular outcomes and safety data beyond Phase 2 trials are not yet fully established.
The exact real-world efficacy compared head-to-head with dual or triple incretin agonists remains to be seen.

06Safety & regulatory context

Regulatory statusPetrelintide is currently an investigational drug in Phase 2/3 clinical trials and is not FDA-approved for any indication. In clinical studies to date, it has demonstrated a favorable safety profile, with the most common side effects being mild to moderate gastrointestinal issues (such as nausea). Notably, it has shown a low discontinuation rate due to GI side effects (around 1.5% in Phase 2). It is contraindicated in individuals with a known hypersensitivity to amylin analogs.

07Compared with Semaglutide

Petrelintide vs. Semaglutide

Key difference

Petrelintide is an amylin analog that primarily promotes satiety and may offer better GI tolerability, whereas semaglutide is a GLP-1 receptor agonist that strongly stimulates insulin secretion and delays gastric emptying, often with higher rates of initial nausea.

When researchers discuss each

Researchers discuss semaglutide as the current standard of care for obesity and type 2 diabetes, while petrelintide is discussed as a promising next-generation alternative or adjunct therapy that targets a different hormonal pathway (amylin) for weight management.

08Glossary

Amylin

A peptide hormone co-secreted with insulin from the pancreas that plays a role in glycemic regulation by slowing gastric emptying and promoting satiety.

Agonist

A substance that binds to a receptor and activates it to produce a biological response.

Satiety

The feeling of fullness and loss of appetite that occurs after eating.

09Knowledge check

Q1What is the primary mechanism of action of petrelintide?

Q2What potential advantage does petrelintide show in early clinical trials compared to some existing weight loss medications?

Q3Which conclusion is best supported by the dossier about petrelintide's current evidence base?

Q4Why do researchers discuss petrelintide in comparison with semaglutide according to the dossier?

Q5Which safety or regulatory statement about petrelintide is supported by the dossier?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism

Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.